Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …
…, R Corre, I Bover, A Illiano, E Dansin… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 …
…, D Debieuvre, PJ Souquet, L Bigay-Game, E Dansin… - The Lancet, 2011 - thelancet.com
Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell
lung cancer (NSCLC) in fit, non-elderly adults, but monotherapy is recommended …
lung cancer (NSCLC) in fit, non-elderly adults, but monotherapy is recommended …
[PDF][PDF] Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
…, T Urban, D Moro-Sibilot, E Dansin… - Journal of clinical …, 2013 - cancer.net
… Cortot, Fabrice Barlesi, Michéle Beau-Faller, Benjamin Besse, Héle`ne Blons, Audrey
Mansuet-Lupo, Thierry Urban, Denis Moro-Sibilot, Eric Dansin, Christos Chouaid, Marie …
Mansuet-Lupo, Thierry Urban, Denis Moro-Sibilot, Eric Dansin, Christos Chouaid, Marie …
Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non–small-cell lung cancer: Groupe …
…, J Le Treut, JA Silvani, E Dansin… - Journal of clinical …, 2005 - ascopubs.org
Purpose We conducted a phase III study to compare the survival impact of concurrent versus
sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage …
sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage …
Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC
B Besse, M Charrier, V Lapierre, E Dansin… - …, 2016 - Taylor & Francis
Dendritic cell-derived exosomes (Dex) are small extracellular vesicles secreted by viable
dendritic cells. In the two phase-I trials that we conducted using the first generation of Dex (IFN-…
dendritic cells. In the two phase-I trials that we conducted using the first generation of Dex (IFN-…
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 …
…, B Lamezec, U Nestle, P Boisselier, E Dansin… - The Lancet …, 2022 - thelancet.com
Background In patients with non-small-cell lung cancer (NSCLC), the use of postoperative
radiotherapy (PORT) has been controversial since 1998, because of one meta-analysis …
radiotherapy (PORT) has been controversial since 1998, because of one meta-analysis …
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
L Crinò, E Dansin, P Garrido, F Griesinger… - The lancet …, 2010 - thelancet.com
Background Results of two phase 3 trials have shown first-line bevacizumab in combination
with chemotherapy improves clinical outcomes in patients with advanced or recurrent non-…
with chemotherapy improves clinical outcomes in patients with advanced or recurrent non-…
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
…, AC Metivier, P Tomasini, E Dansin… - European …, 2017 - Eur Respiratory Soc
Immunotherapy is becoming a standard of care for many cancers. Immune-checkpoint
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
inhibitors (ICI) can generate immune-related adverse events. Interstitial lung disease (ILD) has …
[PDF][PDF] Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized …
…, N Baize, H Bérard, L Falchero, I Monnet, E Dansin… - J Clin …, 2016 - researchgate.net
Purpose Comprehensive geriatric assessment (CGA) is recommended to assess the
vulnerability of elderly patients, but its integration in cancer treatment decision making has never …
vulnerability of elderly patients, but its integration in cancer treatment decision making has never …
[HTML][HTML] Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C …
…, Z Andric, CH Barrios, M Yamaguchi, E Dansin… - Nature medicine, 2022 - nature.com
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open-label, …
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open-label, …